Eric Penanhoat
Lorenz Leitner
Paul Garofolo
Felipe Molina PhD
My research is focused on bacterial genetics, the cell cycle of microorganisms and phages as biocontrol agents in dairy products.
Alexander Sulakvelidze
Dr. Alexander “Sandro” Sulakvelidze, Ph.D. is the President and CEO of Intralytix. He is an internationally recognized expert in phage technology who was instrumental in securing the first ever FDA-approval for phage-based food safety product in the World. Dr. Sulakvelidze has published extensively on the subject of phage therapy and biocontrol, including co-editing a major book about bacteriophages entitled “Bacteriophages: Biology and Applications”. He is the author of 15 issued and several pending patents in the field of bacteriophage technology.
Christian Röhrig
Merav Bassan
Dr. Bassan was most recently Vice President Head of Translational Sciences at Teva Pharmaceutical Industries, Inc., where she was responsible for early stages of clinical development via translation from animal data to human. Prior to this role, Dr. Bassan served as Vice President of Project Leadership at Teva Pharmaceutical, where she managed project leaders overseeing end-to-end drug development at pre-clinical, PI-III and post marketing stages in multiple therapeutic areas, such as pain, oncology, women‘s health, endocrinology, GI, biosimilars and other areas. Overall, Dr. Bassan has over 20 years of leadership experience with clinical and drug development teams in her various roles at Teva Pharmaceutical and other smaller biotech companies. Dr. Bassan is also a member of the Israeli 8400 health network, a cross-sector network of leaders actualizing the global disruptive capabilities of Israel’s HealthTech ecosystem. Dr. Bassan holds a Ph.D. in Neuroscience from the Tel-Aviv University Sackler School of Medicine and completed a post-doctoral fellowship in Neuroscience at Harvard University.